Good evening :)
Place Order
Add to Watchlist

Balaji Amines Ltd

BALAMINES Share Price

1,445.801.27% (+18.10)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹4,685 cr, stock is ranked 793

Stock is 2.71x as volatile as Nifty

BALAMINES Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹4,685 cr, stock is ranked 793

Stock is 2.71x as volatile as Nifty

BALAMINES Performance & Key Metrics

BALAMINES Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
29.752.48
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
27.473.491.58%

BALAMINES Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 1 analyst

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

BALAMINES Company Profile

Balaji Amines Limited is a company, which is engaged in the manufacturing of Aliphatic Amines, their derivatives and specialty chemicals. The Company is running a five star hotel, Balaji Sarovar Premiere.

Investor Presentation

View older View older 

Jun 6, 2025

PDF
View Older Presentations

BALAMINES Similar Stocks (Peers)

Compare with peers Compare with peers 

BALAMINES Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
73.05
73.05
1Y Return
10.57%
10.57%
Buy Reco %
55.56
55.56
PE Ratio
77.56
77.56
1Y Return
31.68%
31.68%
Buy Reco %
62.96
62.96
PE Ratio
48.05
48.05
1Y Return
0.19%
0.19%
Buy Reco %
83.33
83.33
PE Ratio
50.71
50.71
1Y Return
34.80%
34.80%
Buy Reco %
70.59
70.59
PE Ratio
58.93
58.93
1Y Return
5.57%
5.57%
Buy Reco %
60.00
60.00
Compare with Peers

BALAMINES Sentiment Analysis

BALAMINES Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

BALAMINES Stock Summary · November 2024

In Q2 FY25, the company faced a challenging industry environment, resulting in flat revenue streams and a decline in production volume. However, strategic investments in higher-margin products and the successful launch of a new Methyl Amine plant have improved EBITDA margins and are expected to enhance production capacity significantly. While pricing trends are stabilizing, the company remains cautious in the Acetonitrile market due to low margins and international competition. Ongoing capital expenditures in specialty chemicals and battery-related projects reflect a commitment to future growth, despite market risks and operational challenges. Overall, a positive outlook for the API and agrochemical sectors, coupled with advancements in technology and sustainability initiatives, positions the company for potential long-term success.

BALAMINES Stock Growth Drivers
BALAMINES Stock Growth Drivers
7
  • Successful Launch of New Facilities

    The company successfully launched a new Methyl Amine plant, significantly increasing its annual capacity from

  • Improvement in Financial Metrics

    In H1 FY '25, the company reported a Profit After Tax (PAT) of Rs. 81

BALAMINES Stock Challenges
BALAMINES Stock Challenges
4
  • Declining Revenue and Production Volumes

    The company has reported a consistent decline in revenue and production volumes across multiple quarters.

  • Decreased Profitability Metrics

    The company has experienced a decline in key profitability metrics. In Q2 FY '25, Profit

BALAMINES Forecast

BALAMINES Forecasts

Price

Revenue

Earnings

BALAMINES

BALAMINES

Income

Balance Sheet

Cash Flow

BALAMINES Income Statement

BALAMINES Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 12.02%, vs industry avg of 6.07%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 1.69% to 1.88%

Higher than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 11.75%, vs industry avg of -1.24%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue679.74873.36947.28940.781,317.532,337.602,370.651,671.151,430.291,430.29
Raw Materialssubtract347.33460.97541.01497.97615.801,276.411,261.20916.251,164.931,164.93
Power & Fuel Costsubtract57.9476.5284.7095.03125.02209.93237.59169.89
Employee Costsubtract24.4726.8929.4734.0733.5696.6485.2182.27
Selling & Administrative Expensessubtract68.9787.5992.5190.89124.20134.52131.58117.33
Operating & Other expensessubtract22.6927.231.9537.0639.64-17.2830.7032.04
Depreciation/Amortizationsubtract19.7119.2919.5531.6234.4142.0045.5745.3748.4448.43
Interest & Other Itemssubtract12.949.0413.0323.0318.2917.1011.976.443.703.71
Taxes & Other Itemssubtract43.3452.6647.5326.3088.40209.87241.2996.7055.7055.70
EPS25.4234.9336.2732.3573.52113.70100.4763.2348.6248.62
DPS2.202.602.803.204.006.0010.0011.000.0011.00
Payout ratio0.090.070.080.100.050.050.100.170.000.23

BALAMINES Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual Report Pending

Investor Presentation

Jun 6PDF
Mar 20PDF
Feb 14PDF
Nov 19PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Sep 2PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 22PDF
Feb 7PDF
Oct 28PDF
Aug 13PDF
FY 2022FY 2022

Annual report

PDF

Investor Presentation

May 12PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
FY 2015FY 2015

Annual report

PDF
 

BALAMINES Stock Peers

BALAMINES Past Performance & Peer Comparison

BALAMINES Past Performance & Peer Comparison

Comparing 3 stocks from 
MaterialsSpecialty Chemicals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Balaji Amines Ltd29.752.48
Gujarat Fluorochemicals Ltd73.056.72
Navin Fluorine International Ltd77.569.390.27%
Vinati Organics Ltd48.057.910.40%

BALAMINES Stock Price Comparison

Compare BALAMINES with any stock or ETF
Compare BALAMINES with any stock or ETF
BALAMINES
Loading...

BALAMINES Holdings

BALAMINES Shareholdings

BALAMINES Promoter Holdings Trend

BALAMINES Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

BALAMINES Institutional Holdings Trend

BALAMINES Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

BALAMINES Shareholding Pattern

BALAMINES Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding54.62%0.13%1.35%5.08%38.82%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

BALAMINES Shareholding History

BALAMINES Shareholding History

Dec '23MarJunSepDec '24Mar4.57%4.92%5.05%5.27%5.16%5.08%

Mutual Funds Invested in BALAMINES

Mutual Funds Invested in BALAMINES

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Balaji Amines Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.1058%0.21%0.21%306/318 (-1)
0.0005%0.01%-0.00%604/816 (-2)
0.0004%0.01%0.00%431/507 (+4)

Compare 3-month MF holding change on Screener

BALAMINES Insider Trades & Bulk Stock Deals

BALAMINES Insider Trades & Bulk Stock Deals

Loading...

smallcases containing BALAMINES stock

smallcases containing BALAMINES stock

Looks like this stock is not in any smallcase yet.

BALAMINES Events

BALAMINES Events

BALAMINES Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

BALAMINES Dividend Trend

No dividend trend available

BALAMINES Upcoming Dividends

BALAMINES Upcoming Dividends

No upcoming dividends are available

BALAMINES Past Dividends

BALAMINES Past Dividends

Cash Dividend

Ex DateEx DateJul 4, 2024

Final
Final | Div/Share: ₹11.00

Dividend/Share

11.00

Ex DateEx Date

Jul 4, 2024

Cash Dividend

Ex DateEx DateJul 3, 2023

Final
Final | Div/Share: ₹10.00

Dividend/Share

10.00

Ex DateEx Date

Jul 3, 2023

Cash Dividend

Ex DateEx DateJun 21, 2022

Final
Final | Div/Share: ₹6.00

Dividend/Share

6.00

Ex DateEx Date

Jun 21, 2022

Cash Dividend

Ex DateEx DateJul 29, 2021

Final
Final | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

Jul 29, 2021

Cash Dividend

Ex DateEx DateJul 30, 2020

Final
Final | Div/Share: ₹0.60

Dividend/Share

0.60

Ex DateEx Date

Jul 30, 2020

BALAMINES Stock News & Opinions

BALAMINES Stock News & Opinions

Earnings
Balaji Amines consolidated net profit declines 41.11% in the March 2025 quarter

Net profit of Balaji Amines declined 41.11% to Rs 40.06 crore in the quarter ended March 2025 as against Rs 68.03 crore during the previous quarter ended March 2024. Sales declined 14.79% to Rs 352.73 crore in the quarter ended March 2025 as against Rs 413.94 crore during the previous quarter ended March 2024. For the full year,net profit declined 23.10% to Rs 157.52 crore in the year ended March 2025 as against Rs 204.85 crore during the previous year ended March 2024. Sales declined 14.89% to Rs 1397.08 crore in the year ended March 2025 as against Rs 1641.51 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales352.73413.94 -15 1397.081641.51 -15 OPM %16.9123.60 -16.6219.72 - PBDT66.84105.16 -36 261.66346.93 -25 PBT53.9492.91 -42 213.22301.56 -29 NP40.0668.03 -41 157.52204.85 -23 Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
Balaji Amines slides as Q4 PAT slumps 44% YoY to Rs 40 cr

Profit before tax (PBT) stood at Rs 53.93 crore in Q4 FY25, down 41.94% year-on-year but up 31.89% quarter-on-quarter. EBITDA stood at Rs 68 crore in Q4 FY25, down 35.84% year-on-year but up 25.92% quarter-on-quarter. EBITDA margin declined to 19% in Q4 FY25, compared to 25% in Q4 FY24 and 17% in Q3 FY25. Total expenses fell 6.96% to Rs 306.82 crore in Q4 FY25 over Q4 FY24. During the quarter, the cost of materials consumed stood at Rs 180.64 crore (down 25.84% YoY), while employee benefits expense was at Rs 22.88 crore (down 6.72% YoY). The company's revenue from the amines amines derivatives volumes stood at 8,389 MT, and specialty chemicals volumes stood at 7,342 MT. On a full year basis, the company's consolidated net profit tanked 31.73% to Rs 158.59 crore on 14.89% decline in revenue from operations to Rs 1,397.08 crore in FY25 over FY24. On the performance, D. Ram Reddy, Managing Director, commented, 'During Q4 FY25, our business performance showed improvement compared to the rest of the financial year, supported by favorable global macroeconomic conditions. As volume uptake gradually increases, we expect EBITDA and PAT margins to improve in line with broader industry recovery trends. However, geopolitical tensions and tariff-related challenges across global markets may continue to impact growth across several sectors in which we operate. These factors have weighed on domestic demand, but we anticipate that better utilization of expanded capacities will support margin recovery in the coming quarters. Pharmaceutical sector demand remained steady, contributing to base volumes, while the agrochemical segment exhibited volatility during the quarter. We continue to make progress on our strategic capex initiatives, including Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether projects, which are moving forward as planned. On the sustainability front, we are pleased to announce that our 6 MW AC Solar Power Plant was commissioned on 2 nd April, 2025. The plant is being brought online in a phased manner under Grid Connectivity, and the power generated will be utilized for captive consumption. Looking ahead, we remain focused on enhancing operational efficiencies, managing input costs and expanding our product portfolio to deliver sustained value to all stakeholders.' Meanwhile, Balaji Amines, through its subsidiary Balaji Speciality Chemicals, is investing approximately Rs 750 crore in a new expansion project. The greenfield project will manufacture a range of products, including Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN) 30% solution and 100% solid, EDTA/EDTA-2Na, Benzyl Cyanide (BnCN), Phenylacetic Acid (PAA), and Triethyl Orthoformate (TEOF)/Trimethyl Orthoformate (TMOF). This project is currently under execution and is expected to be commissioned by the end of FY 2025-26. Additionally, a brownfield project for manufacturing EDA-based products at Unit-I is progressing as planned and is expected to be commissioned in FY 2026-27. Further, the company has recommended a final dividend of Rs 11 per equity share, which translates to 550% on a face value of Rs 2 per share. The dividend will be payable subject to approval by the shareholders at the 37th Annual General Meeting of the company. The board has approved the re-appointment of A. Prathap Reddy as executive chairman of the company for a period of five years, effective from 1 April 2026, subject to shareholder approval. Additionally, the board has approved the re-appointment of D. Ram Reddy as managing director for a further term of five years, also effective from 1 April 2026, pending shareholder approval. Balaji Amines is a leading manufacturer of aliphatic amines in India. Broadly, the company is specialized in manufacturing methyl amines, ethyl amines, derivatives of specialty chemicals, and natural products, and its business is broadly classified into three segments: amines, specialty chemicals, and derivatives. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Board of Balaji Amines recommends final dividend

Balaji Amines announced that the Board of Directors of the Company at its meeting held on 28 May 2025, inter alia, have recommended the final dividend of Rs 11 per equity Share (i.e. 550%) , subject to the approval of the shareholders.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Balaji Amines revises board meeting date

Balaji Amines has revised the meeting of the Board of Directors which was scheduled to be held on 26 May 2025. The meeting will now be held on 28 May 2025.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Balaji Amines to conduct board meeting

Balaji Amines will hold a meeting of the Board of Directors of the Company on 26 May 2025.Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Spotlight
Balaji Amines drops as Q3 PAT slides 18% YoY to Rs 33 cr

Profit before tax slipped 41.81% year on year to Rs 40.89 crore in the quarter ended 31 December 2024. EBITDA for Q3 FY25 stood at Rs 54 crore, down 34.94%, compared to Rs 83 crore in Q3 FY24. EBITDA margin for Q3 FY25 was reduced to 17% in Q3 FY25 as against 21% reported in the same period a year ago. Total expense declined 13.02% YoY to Rs 279.70 crore during the quarter. Cost of raw material consumed stood at Rs 168.50 crore (down 16.29% YoY), while employee benefits expenses were at Rs 18.53 crore (down 9.83% YoY) in Q3 FY25. The company's revenue from the amines amines derivatives volumes stood at 8,809 MT, and specialty chemicals volumes stood at 7,773 MT. On a standalone basis, the company's net profit declined 14.1% to Rs 35.69 crore in Q3 FY25 as against Rs 41.55 crore posted in Q3 FY24. Revenue from operations was at Rs 299.23 crore in Q3 FY25, down 2.79% YoY. Meanwhile, the company has installed rooftop solar plants at various locations, and the Maharashtra State Electricity Distribution Company (MSEDCL) has approved these installations. The capacities of these solar units for captive consumption are 2.655 MW, and the expected unit generated is approximately 12 lakh units. D. Ram Reddy, MD, Balaji Amines, said, 'During Q3 FY25, our financial and business performance remained stable despite the challenges posed by global macroeconomic conditions. However, as volume uptake gradually increases, EBITDA and PAT margins are expected to improve in line with industry recovery. The resurgence in domestic demand, along with positive trends in international markets, is driving this momentum. Additionally, the utilization of expanded capacities will contribute to margin enhancement as some of our products progress through the final approval stages with end-user industries. This progress is further supported by our ongoing investments in key projects, reinforcing our commitment to operational excellence. Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether projects are progressing well, aligning with our strategic growth objectives. These initiatives are designed to strengthen our market presence, enhance product offerings, and meet the evolving needs of our customers. Looking ahead, we maintain a positive outlook for long-term opportunities, anticipating growth and increased prospects during the fiscal year 2025-26. Our focus on inherent strengths and competencies positions us as a leading force in amines and specialty chemicals, guiding us through market complexities towards greater excellence.' Balaji Amines is a leading manufacturer of aliphatic amines in India. Broadly, the company is specialized in manufacturing methyl amines, ethyl amines, derivatives of specialty chemicals, and natural products, and its business is broadly classified into three segments: amines, specialty chemicals, and derivatives.Powered by Capital Market - Live

4 months agoCapital Market - Live
Earnings
Balaji Amines consolidated net profit declines 32.77% in the December 2024 quarter

Net profit of Balaji Amines declined 32.77% to Rs 33.19 crore in the quarter ended December 2024 as against Rs 49.37 crore during the previous quarter ended December 2023. Sales declined 18.42% to Rs 312.73 crore in the quarter ended December 2024 as against Rs 383.36 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales312.73383.36 -18 OPM %14.6219.36 - PBDT52.7781.12 -35 PBT40.8970.27 -42 NP33.1949.37 -33 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Balaji Amines to hold board meeting

Balaji Amines will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live

4 months agoCapital Market - Live
Spotlight
Balaji Amines Q2 PAT rises 18% YoY to Rs 41 crore

Revenue from operations declined 8.85% year on year (YoY) to Rs 346.88 crore in the quarter ended 30 September 2024. Profit before tax stood at Rs 56.81 crore in September 2024 quarter, registering a growth of 18.33% on YoY basis. Sequentially, the company's net profit and revenue from operations in second quarter of FY25 declined 5.34% and 9.84%, respectively. EBITDA during the quarter stood at Rs 70 crore, down 5.41% as compared to Rs 74 crore in Q1 of FY25. EBITDA margin for Q2FY25 improved to 20% in Q2 FY25 as against 19% reported in the same period a year ago. Total expenses declined 11.8% YoY to Rs 299.26 crore during the quarter. Cost of raw material consumed stood at Rs 221.88 crore (up 16% YoY) while other expenses were at Rs 78.92 crore (down 7.31% YoY) in Q2 FY25. The company's revenue from amines amines derivatives volumes stood at 8,685 MT and specialty chemicals volumes stood at 10,046 MT. Looking ahead, Balaji Amines is proposing to set up a plant for manufacture of N-(N-Butyl) Thiophosphoric Triamide (NBPT) with a capacity of 2500 TPA which will be taken up next Financial Year. Additionally, the company aims to expand its ACN production capacity by setting up a new plant with a 60 MT/day capacity at Unit-III in MIDC, Chincholi. The discussion for transfer of the latest technology (reducing the cost of production) is under final stage and the company may sign the agreement by the end of November 2024. New equipment as per the latest technology will be integrated with the existing ACN plant at Unit-III. In a separate development, Balaji Speciality Chemicals, a subsidiary of Balaji Amines, has planned a major expansion with an investment of approximately Rs 750 c rore. This project will focus on a range of products, including Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN) in both 30% solution and 100% solid forms, EDTA, EDTA-2Na, Benzyl Cyanide (BnCN), Phenylacetic Acid (PAA), and Tri Ethyl Ortho Formate (TEOF)/Tri Methyl Ortho Formate (TMOF). D. Ram Reddy, managing director, Balaji Amines, said, 'In the Q2 quarter, we reported a revenue of Rs 356 crore, achieving an EBITDA margin of 20%. This marks a 110-basis-point improvement over last quarter, reflecting our focus on higher margin products amid a challenging industry environment. While the broader market experienced pressure in Q2, both the API and agrochemical looks promising over a long term, and we are well-positioned to seize these future opportunities. With our expanded capacities and a sharpened focus on operational efficiency, we are confident in our ability to drive sustainable growth in the coming quarters. Our recent developments demonstrate significant progress in expanding our production capacity. With the successful commencement of Methylamines production at Unit-IV, our total annual installed capacity has increased from 48,000 MT to 88,000 MT across all three units. Additionally, Unit-I and Unit-III have achieved BIS Certification for 'Morpholine,' strengthening our quality standards and making us the only BIS-certified Morpholine manufacturer in India. Projects in Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether are also advancing well, reflecting our commitment to operational excellence. As we look forward, our strong foundation in core capabilities positions us well to navigate industry dynamics and capture growth opportunities.' Balaji Amines is a leading manufacturer of aliphatic amines in India. Broadly, the company is specialized in manufacturing methyl amines, ethyl amines, derivatives of specialty chemicals and natural product and its business is broadly classified into three segments - amines, specialty chemicals and derivatives. Shares of Balaji Amines declined 1.92% to Rs 1,996.15 on the BSE. Powered by Capital Market - Live

6 months agoCapital Market - Live
Earnings
Balaji Amines consolidated net profit rises 18.06% in the September 2024 quarter

Net profit of Balaji Amines rose 18.06% to Rs 40.98 crore in the quarter ended September 2024 as against Rs 34.71 crore during the previous quarter ended September 2023. Sales declined 8.85% to Rs 346.88 crore in the quarter ended September 2024 as against Rs 380.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales346.88380.54 -9 OPM %17.4914.14 - PBDT68.8158.79 17 PBT56.8148.01 18 NP40.9834.71 18 Powered by Capital Market - Live

7 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Balaji Amines Ltd (BALAMINES) today?

    The share price of BALAMINES as on 18th June 2025 is ₹1445.80. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Balaji Amines Ltd (BALAMINES) share?

    The past returns of Balaji Amines Ltd (BALAMINES) share are
    • Past 1 week: -4.92%
    • Past 1 month: 0.96%
    • Past 3 months: 19.48%
    • Past 6 months: -27.64%
    • Past 1 year: -35.69%
    • Past 3 years: -48.46%
    • Past 5 years: 235.37%

  3. What are the peers or stocks similar to Balaji Amines Ltd (BALAMINES)?
  4. What is the market cap of Balaji Amines Ltd (BALAMINES) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Balaji Amines Ltd (BALAMINES) is ₹4685.83 Cr as of 18th June 2025.

  5. What is the 52 week high and low of Balaji Amines Ltd (BALAMINES) share?

    The 52-week high of Balaji Amines Ltd (BALAMINES) is ₹2549.75 and the 52-week low is ₹1127.55.

  6. What is the PE and PB ratio of Balaji Amines Ltd (BALAMINES) stock?

    The P/E (price-to-earnings) ratio of Balaji Amines Ltd (BALAMINES) is 29.75. The P/B (price-to-book) ratio is 2.48.

  7. Which sector does Balaji Amines Ltd (BALAMINES) belong to?

    Balaji Amines Ltd (BALAMINES) belongs to the Materials sector & Specialty Chemicals sub-sector.

  8. How to buy Balaji Amines Ltd (BALAMINES) shares?

    You can directly buy Balaji Amines Ltd (BALAMINES) shares on Tickertape. Simply sign up, connect your demat account and place your order.